Published Online
on February 28, 2008

A more recent version of this article appeared on April 1, 2008

This Article Full Text (PDF) All Versions of this Article: 39/4/1389    most recent STROKEAHA.107.504415v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Savitz, S. I. Articles by Schäbitz, W.-R. Search for Related Content PubMed PubMed Citation Articles by Savitz, S. I. Articles by Schäbitz, W.-R. Related Collections Neuroprotectors

Submitted on September 12, 2007
Accepted on September 13, 2007

A Critique of SAINT II. Wishful Thinking, Dashed Hopes, and the Future of Neuroprotection for Acute Stroke

Sean I. Savitz MD and Wolf-Rüdiger Schäbitz MD^*

From the Department of Neurology (S.I.S.), University of Texas Houston Medical School, Houston, Texas; and the Department of Neurology (W.-R.S.), University of Münster, Münster, Germany.

^* To whom correspondence should be addressed. E-mail: sean.i.savitz{at}uth.tmc.edu.

Key words: acute stroke • neuroprotection

This article has been cited by other articles:

				C. L Gibson, B. Coomber, and J. Rathbone Is Progesterone a Candidate Neuroprotective Factor for Treatment following Ischemic Stroke? Neuroscientist, August 1, 2009; 15(4): 324 - 332. [Abstract] [PDF]

				A. M. Dorrance Stroke Therapy: Is Spironolactone the Holy Grail? Endocrinology, August 1, 2008; 149(8): 3761 - 3763. [Full Text] [PDF]